3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Warts
2
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Condylomata Acuminata
1
Interventions
Cryotherapy
11
resiquimod
6
Cantharidin
5
PRA1 protein, Candida albicans
4
Tuberculin
3
Salicylic Acid
3
Cholecalciferol
3
plerixafor
2
VP-102
2
Solutions
2
Sodium Chloride
2
Saline Solution
2
Photochemotherapy
2
Percutaneous Collagen Induction
2
N-phenylacetoaminomethylene-DL-p-nitrophenylalanine
2
Measles-Mumps-Rubella Vaccine
2
Lasers
2
Hydrogen Peroxide
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
3-ingenyl angelate
2
2-Propanol
2
methyl 5-aminolevulinate
1
lactic acid, salicylic acid drug combination
1
human papillomavirus vaccine, L1 type 16, 18
1
green tea extract polyphenone E
1
gluconic acid
1
ethyl pyruvate
1
compound W
1
ammonium trichloro(dioxoethylene-O,O'-)tellurate
1
Zinc Sulfate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Warts
×
VP-102
×
Clear all
NCT07246590
2026-01-21
COVE-2
Verrica Pharmaceuticals Inc.
Phase 3
Recruiting
300 enrolled
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts